Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/pharmaceutics13040494 http://scihub22266oqcxt.onion/10.3390/pharmaceutics13040494 33916409!8065592!33916409     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmaceutics 2021 ; 13 (4): ä Nephropedia Template TP {{tp|p=33916409|t=2021. Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics |pdf=|usr=}}{{33916409}} gab.com Text Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics JO: Pharmaceutics http://www.kidney.de/pget.php?&tw=1&pmid=33916409 #FOAvip An increasing number of clinical studies worldwide are investigating the repurposing of antiviral, immune-modulatory, and anti-inflammatory agents to face the coronavirus disease-19 (COVID-19) pandemic. Nevertheless, few effective therapies exist to prevent or treat COVID-19, which demands increased drug discovery and repurposing efforts. In fact, many currently tested drugs show unknown efficacy and unpredictable drug interactions, such that interventions are needed to guarantee access to effective and safe medicines. Anti-inflammatory therapy has proven to be effective in preventing further injury in COVID-19 patients, but the benefit comes at a cost, as targeting inflammatory pathways can imply an increased risk of infection. Thus, optimization of the risk/benefit ratio is required in the anti-inflammatory strategy against COVID-19, which accounts for drug formulations and delivery towards regionalization and personalization of treatment approaches. In this perspective, we discuss how better knowledge of endogenous immunomodulatory pathways may optimize the clinical use of novel and repurposed drugs against COVID-19 in inpatient, outpatient, and home settings through innovative drug discovery, appropriate drug delivery systems and dedicated molecular pharmaceutics. Twit Text FOAVip Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics ????Pharmaceutics http://www.kidney.de/pget.php?&tw=1&pmid=33916409 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33916409 #FOAvip English Wikipedia <ref>{{Cite pmid|33916409}}</ref> Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics #MMPMID33916409 Puccetti M; Costantini C; Ricci M; Giovagnoli S Pharmaceutics 2021[Apr]; 13 (4): ä PMID33916409show ga An increasing number of clinical studies worldwide are investigating the repurposing of antiviral, immune-modulatory, and anti-inflammatory agents to face the coronavirus disease-19 (COVID-19) pandemic. Nevertheless, few effective therapies exist to prevent or treat COVID-19, which demands increased drug discovery and repurposing efforts. In fact, many currently tested drugs show unknown efficacy and unpredictable drug interactions, such that interventions are needed to guarantee access to effective and safe medicines. Anti-inflammatory therapy has proven to be effective in preventing further injury in COVID-19 patients, but the benefit comes at a cost, as targeting inflammatory pathways can imply an increased risk of infection. Thus, optimization of the risk/benefit ratio is required in the anti-inflammatory strategy against COVID-19, which accounts for drug formulations and delivery towards regionalization and personalization of treatment approaches. In this perspective, we discuss how better knowledge of endogenous immunomodulatory pathways may optimize the clinical use of novel and repurposed drugs against COVID-19 in inpatient, outpatient, and home settings through innovative drug discovery, appropriate drug delivery systems and dedicated molecular pharmaceutics. äTackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceuti(epmc).pdf DeepDyve Pubget Overpricing